Aprepitant for Postoperative Nausea and Vomiting in Laparoscopic Hysterectomy

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

• Gynecological surgery is associated with a high incidence of postoperative nausea and vomiting.

• NK1 receptor antagonists such as aprepitant appear to be highly effective for treating acute and delayed emesis, and yet understanding of the efficacy of different doses of aprepitant is limited.

• We performed a prospective, randomized, double-blinded placebo-controlled study of 123 female adults scheduled for laparoscopic hysterectomy who received 80 mg aprepitant, 125 mg aprepitant, or a placebo.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gachon University Gil Medical Center
• Collaborators: Asan Medical Center; University of California, San Francisco
• Treatments: Aprepitant; Fosaprepitant

Criteria

Inclusion Criteria:

• female laparoscopic hysterectomy isoflurane anesthesia postoperative opioid use

Exclusion Criteria:

• liver disease neurologic disease active pulmonary disease cardiac arrhythmia allergies to any perioperative medications